Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Tran, Ben
Horvath, Lisa
Dorff, Tanya B.
Greil, Richard
Machiels, Jean-Pascal H.
Roncolato, Felicia
Autio, Karen A.
Rettig, Matthew
Fizazi, Karim
Lolkema, Martijn P.
Fermin, Anthony C.
Salvati, Mark
Kouros-Mehr, Hosein
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Chris OBrien Lifehouse, Camperdown, NSW, Australia
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Paracelsus Med Univ Salzburg, Salzburg Canc Res Inst CCCIT, Salzburg, Austria
[5] Canc Cluster Salzburg, Salzburg, Austria
[6] Clin Univ St Luc, Brussels, Belgium
[7] Scientia Clin Res, Randwick, NSW, Australia
[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[9] Univ Calif Los Angeles, Los Angeles, CA USA
[10] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[11] Erasmus MC Canc Inst, Rotterdam, Netherlands
[12] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS261
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).
    Hummel, Horst-Dieter
    Kufer, Peter
    Gruellich, Carsten
    Deschler-Baier, Barbara
    Chatterjee, Manik
    Goebeler, Maria-Elisabeth
    Miller, Kurt
    De Santis, Maria
    Loidl, Wolfgang C.
    Buck, Andreas
    Wittemer-Rump, Sabine
    Koca, Goekben
    Boix, Oliver
    Doecke, Wolf-Dietrich
    Stienen, Sabine
    Sayehli, Cyrus
    Bargou, Ralf C.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [12] Combination of AMG 160, a PSMA x CD3 half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, with an anti-PD-1 antibody in prostate cancer (PCa)
    Paweletz, Katherine L.
    Li, Shyun
    Bailis, Julie M.
    Juan, Gloria
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [13] Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).
    Owonikoko, Taofeek Kunle
    Borghaei, Hossein
    Champiat, Stephane
    Paz-Ares, Luis G.
    Govindan, Ramaswamy
    Boyer, Michael J.
    Johnson, Melissa Lynne
    Udagawa, Hibiki
    Hummel, Horst-Dieter
    Salgia, Ravi
    Blackhall, Fiona Helen
    Boosman, Rene J.
    Lai, Wei-Chu Victoria
    Dowlati, Afshin
    Vokes, Everett E.
    Hann, Christine L.
    Chiang, Anne C.
    Endraca, Marichu
    Soman, Neelesh
    Smit, Marie-Anne Damiette
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [14] A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer
    Lordick, F.
    Buxo Orra, E.
    Cervantes, A.
    Dayyani, F.
    Rocha-Lima, C.
    Greil, R.
    van Laarhoven, H.
    Lorenzen, S.
    Kischel, R.
    Shitara, K.
    Chao, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S114 - S114
  • [15] AMG 757, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE® Immune Therapy) Targeting DLL3, for the Treatment of Small Cell Lung Cancer
    Cooke, K.
    Estrada, J.
    Zhan, J.
    Werner, J.
    Bailis, J.
    Hughes, P.
    Shetty, A.
    Canon, J.
    Smit, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S343 - S344
  • [16] Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).
    De Bono, Johann S.
    Fong, Lawrence
    Beer, Tomasz M.
    Gao, Xin
    Geynisman, Daniel M.
    Burris, Howard A., III
    Strauss, James Fredric
    Courtney, Kevin Dale
    Quinn, David I.
    VanderWeele, David James
    Yaron, Yifah
    Law, Che-Leung
    Stein, Mark N.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [17] Association between bispecific T cell engager (BiTE) therapy and inflammatory adverse effects (AEs) in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Xu, Michael
    Wummer, Brandon
    Kelly, William Kevin
    Bashir, Babar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [18] Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
    Chao, Joseph
    Buxo, Elvira
    Cervantes, Andres
    Dayyani, Farshid
    Rocha Lima, Caio Max Sao Pedro
    Greil, Richard
    Van Laarhoven, Hanneke W. M.
    Lorenzen, Sylvie
    Heinemann, Volker
    Kischel, Roman
    Shitara, Kohei
    Lordick, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [19] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Blattman, Sara
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [20] Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously treated with a taxane
    Petrylak, Daniel Peter
    Kantoff, Philip W.
    Mega, Anthony E.
    Vogelzang, Nicholas J.
    Stephenson, Joe
    Fleming, Mark T.
    Stambler, Nancy
    Petrini, Michaela
    Huang, Kathleen
    Israel, Robert Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345